Trial Profile

A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berzosertib (Primary) ; Lurbinectedin (Primary)
Indications Neuroendocrine carcinoma; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

17 Mar 2026 Status changed from recruiting to active, no longer recruiting.
02 May 2024 Planned number of patients changed from 75 to 120.
08 Dec 2023 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com